Erik Wist
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics, Childhood Cancer Survivors' Quality of Life, Cancer survivorship and care
Most-Cited Works
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,957 cited
- → 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial(2007)1,506 cited
- → Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial(2000)342 cited
- → Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study(2010)292 cited
- → Gonadal Hormones in Long-Term Survivors 10 Years after Treatment for Unilateral Testicular Cancer(2003)195 cited
- → Predictors and course of chronic fatigue in long-term breast cancer survivors(2010)191 cited
- → Fear of recurrence in long‐term testicular cancer survivors(2008)180 cited
- → Study of Anxiety Disorder and Depression in Long-Term Survivors of Testicular Cancer(2005)175 cited
- The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.(2002)
- → Side Effects and Cancer-Related Stress Determine Quality of Life in Long-Term Survivors of Testicular Cancer(2005)124 cited